Product Code: IRTNTR6118
About Colorectal Cancer
Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Colorectal cancer is the third most common cancer in the US. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.
Technavio's analysts forecast the global colorectal cancer drugs market to grow at a CAGR of 3.62% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer.
Based on the type of molecule, the market is grouped into two categories:
- Biologics
- Small molecules
Based on the route of administration, the market is grouped into two categories:
This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019 in the following regions:
- Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
- EMEA: The principal countries focused upon in this region are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE. Germany, Italy, and the UK are the leading European countries in terms of elderly population
- APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors as well as the competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.
Technavio's report, Global Colorectal Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global colorectal cancer drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Key Vendors
- Amgen
- Bayer
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Merck Serono
Other Prominent Vendors
- Accord Healthcare
- Advenchen Laboratories
- Aeterna Zentaris
- AstraZeneca
- Bavarian Nordic
- Biothera
- Boehringer Ingelheim
- Daiichi Sankyo
- Debiopharm
- Eisai
- Eli Lilly
- Immodulon Therapeutics
- Mologen
- Mylan
- Nektar Therapeutics
- Oncothyreon
- Otsuka Pharmaceutical
- Precision Biologics
- Sun Pharmaceutical
- Symphogen
- Taiho
- Takeda
- Teva
- ThromboGenics
- Xbiotech
- Yakult Honsha
Market Driver
- Increase in population of patients
- For a full, detailed list, view our report
Market Challenge
- Loss of patent exclusivity
- For a full, detailed list, view our report
Market Trend
- Dominance of biologics
- For a full, detailed list, view our report
Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Table of Contents
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
- 03.1. Market Overview
- 03.2. Product Offerings
04. Market Research Methodology
- 04.1. Market Research Process
- 04.2. Research Methodology
05. Introduction
06. Disease Overview
- 06.1. Understanding the Disease
- 06.2. Pathophysiology
- 06.3. Epidemiology
- 06.4. Diagnosis
- 06.5. Staging
- 06.5.1. Staging: Colon Cancer
- 06.5.2. Staging: Rectal Cancer
- 06.6. Management
- 06.7. Economic Burden
07. Market Landscape
- 07.1. Market Overview
- 07.2. Market Size and Forecast
- 07.2.1. Colorectal Cancer Drugs Market in US
- 07.2.2. Colorectal Cancer Drugs Market in Germany
- 07.2.3. Colorectal Cancer Drugs Market in Spain
- 07.2.4. Colorectal Cancer Drugs Market in Japan
- 07.2.5. Colorectal Cancer Drugs Market in China
- 07.3. Five Forces Analysis
08. Market Segmentation by Type of Molecules
- 08.1. Small molecules
- 08.2. Biologics
09. Market Segmentation by Route of Administration
- 09.1. Oral
- 09.2. Parenteral
10. Geographical Segmentation
- 10.1. Colorectal Cancer Drugs Market in Americas
- 10.1.1. Market Size and Forecast
- 10.2. Colorectal Cancer Drugs Market in EMEA
- 10.2.1. Market Size and Forecast
- 10.3. Colorectal Cancer Drugs Market in APAC
- 10.3.1. Market Size and Forecast
11. Key Leading Countries
- 11.1. US
- 11.2. Japan
- 11.3. Germany
- 11.4. Spain
- 11.5. China
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
- 19.1. Competitive Scenario
- 19.1.1. Key News
- 19.1.2. Mergers and Acquisitions
- 19.2. Market Share Analysis 2014
- 19.2.1. Competitive Assessment of Top Drugs for Colorectal Cancer
- 19.2.2. F. Hoffmann-La Roche
- 19.2.3. Merck Serono
- 19.2.4. Bristol-Myers Squibb
- 19.2.5. Amgen
- 19.2.6. Sanofi
- 19.2.7. Bayer
- 19.3. Other and Future Prominent Vendors
20. Key Takeaways
21. Key Vendor Analysis
- 21.1. Amgen
- 21.1.1. Key Facts
- 21.1.2. Business Overview
- 21.1.3. Business Segmentation by Revenue 2013
- 21.1.4. Product Portfolio by Revenue 2013
- 21.1.5. Business Segmentation by Revenue 2012 and 2013
- 21.1.6. Geographical Segmentation by Revenue 2013
- 21.1.7. Business Strategy
- 21.1.8. Recent Developments
- 21.1.9. SWOT Analysis
- 21.2. Bayer
- 21.2.1. Key facts
- 21.2.2. Business overview
- 21.2.3. Business segmentation by revenue 2014
- 21.2.4. Business segmentation by revenue 2013 and 2014
- 21.2.5. Geographical segmentation by revenue 2014
- 21.2.6. Business strategy
- 21.2.7. Recent developments
- 21.2.8. SWOT analysis
- 21.3. Bristol-Myers Squibb Co.
- 21.3.1. Key Facts
- 21.3.2. Business Overview
- 21.3.3. Key Product Offerings
- 21.3.4. Revenue by Geography
- 21.3.5. Business Strategy
- 21.3.6. Key Information
- 21.3.7. SWOT Analysis
- 21.4. F. Hoffmann-La Roche Ltd.
- 21.4.1. Key Facts
- 21.4.2. Business Overview
- 21.4.3. Business Segmentation
- 21.4.4. Business Segmentation by Revenue 2012 and 2013
- 21.4.5. Sales by Geography
- 21.4.6. Business Strategy
- 21.4.7. Key Information
- 21.4.8. SWOT Analysis
- 21.5. Merck Serono
- 21.5.1. Key Facts
- 21.5.2. Business Overview
- 21.5.3. Geographical Segmentation by Revenue 2013
- 21.5.4. Business Strategy
- 21.5.5. Recent Developments
- 21.5.6. SWOT Analysis
- 21.6. Sanofi SA
- 21.6.1. Key Facts
- 21.6.2. Business Description
- 21.6.3. Business Segmentation
- 21.6.4. Revenue by Business Segmentation
- 21.6.5. Revenue Comparison 2012 and 2013
- 21.6.6. Sales by Geography
- 21.6.7. Business Strategy
- 21.6.8. Key Developments
- 21.6.9. SWOT Analysis
22. Other Reports in this Series
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
- 03.1. Market Overview
- 03.2. Product Offerings
04. Market Research Methodology
- 04.1. Market Research Process
- 04.2. Research Methodology
05. Introduction
06. Disease Overview
- 06.1. Understanding the Disease
- 06.2. Pathophysiology
- 06.3. Epidemiology
- 06.4. Diagnosis
- 06.5. Staging
- 06.5.1. Staging: Colon Cancer
- 06.5.2. Staging: Rectal Cancer
- 06.6. Management
- 06.7. Economic Burden
07. Market Landscape
- 07.1. Market Overview
- 07.2. Market Size and Forecast
- 07.2.1. Colorectal Cancer Drugs Market in US
- 07.2.2. Colorectal Cancer Drugs Market in Germany
- 07.2.3. Colorectal Cancer Drugs Market in Spain
- 07.2.4. Colorectal Cancer Drugs Market in Japan
- 07.2.5. Colorectal Cancer Drugs Market in China
- 07.3. Five Forces Analysis
08. Market Segmentation by Type of Molecules
- 08.1. Small molecules
- 08.2. Biologics
09. Market Segmentation by Route of Administration
- 09.1. Oral
- 09.2. Parenteral
10. Geographical Segmentation
- 10.1. Colorectal Cancer Drugs Market in Americas
- 10.1.1. Market Size and Forecast
- 10.2. Colorectal Cancer Drugs Market in EMEA
- 10.2.1. Market Size and Forecast
- 10.3. Colorectal Cancer Drugs Market in APAC
- 10.3.1. Market Size and Forecast
11. Key Leading Countries
- 11.1. US
- 11.2. Japan
- 11.3. Germany
- 11.4. Spain
- 11.5. China
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
- 19.1. Competitive Scenario
- 19.1.1. Key News
- 19.1.2. Mergers and Acquisitions
- 19.2. Market Share Analysis 2014
- 19.2.1. Competitive Assessment of Top Drugs for Colorectal Cancer
- 19.2.2. F. Hoffmann-La Roche
- 19.2.3. Merck Serono
- 19.2.4. Bristol-Myers Squibb
- 19.2.5. Amgen
- 19.2.6. Sanofi
- 19.2.7. Bayer
- 19.3. Other and Future Prominent Vendors
20. Key Takeaways
21. Key Vendor Analysis
- 21.1. Amgen
- 21.1.1. Key Facts
- 21.1.2. Business Overview
- 21.1.3. Business Segmentation by Revenue 2013
- 21.1.4. Product Portfolio by Revenue 2013
- 21.1.5. Business Segmentation by Revenue 2012 and 2013
- 21.1.6. Geographical Segmentation by Revenue 2013
- 21.1.7. Business Strategy
- 21.1.8. Recent Developments
- 21.1.9. SWOT Analysis
- 21.2. Bayer
- 21.2.1. Key facts
- 21.2.2. Business overview
- 21.2.3. Business segmentation by revenue 2014
- 21.2.4. Business segmentation by revenue 2013 and 2014
- 21.2.5. Geographical segmentation by revenue 2014
- 21.2.6. Business strategy
- 21.2.7. Recent developments
- 21.2.8. SWOT analysis
- 21.3. Bristol-Myers Squibb Co.
- 21.3.1. Key Facts
- 21.3.2. Business Overview
- 21.3.3. Key Product Offerings
- 21.3.4. Revenue by Geography
- 21.3.5. Business Strategy
- 21.3.6. Key Information
- 21.3.7. SWOT Analysis
- 21.4. F. Hoffmann-La Roche Ltd.
- 21.4.1. Key Facts
- 21.4.2. Business Overview
- 21.4.3. Business Segmentation
- 21.4.4. Business Segmentation by Revenue 2012 and 2013
- 21.4.5. Sales by Geography
- 21.4.6. Business Strategy
- 21.4.7. Key Information
- 21.4.8. SWOT Analysis
- 21.5. Merck Serono
- 21.5.1. Key Facts
- 21.5.2. Business Overview
- 21.5.3. Geographical Segmentation by Revenue 2013
- 21.5.4. Business Strategy
- 21.5.5. Recent Developments
- 21.5.6. SWOT Analysis
- 21.6. Sanofi SA
- 21.6.1. Key Facts
- 21.6.2. Business Description
- 21.6.3. Business Segmentation
- 21.6.4. Revenue by Business Segmentation
- 21.6.5. Revenue Comparison 2012 and 2013
- 21.6.6. Sales by Geography
- 21.6.7. Business Strategy
- 21.6.8. Key Developments
- 21.6.9. SWOT Analysis
22. Other Reports in this Series
List of Exhibits
- Exhibit 1: Market Research Methodology
- Exhibit 2: Drivers and Challenges of the Global Colorectal Cancer Drugs Market
- Exhibit 3: Diagnosis of Colorectal Cancer
- Exhibit 4: Management of Colorectal Cancer
- Exhibit 5: A Snapshot of the Economic Burden of the Global Colorectal Cancer Drugs Market
- Exhibit 6: Snapshot of the Global Colorectal Cancer Drugs Market
- Exhibit 7: Global Colorectal Cancer Drugs Market 2014-2019 ($ millions)
- Exhibit 8: Colorectal Cancer Drugs Market in US 2014-2019 ($ millions)
- Exhibit 9: Colorectal Cancer Drugs Market in Germany 2014-2019 ($ millions)
- Exhibit 10: Colorectal Cancer Drugs Market in Spain 2014-2019 ($ millions)
- Exhibit 11: Colorectal Cancer Drugs Market in Japan 2014-2019 ($ millions)
- Exhibit 12: Colorectal Cancer Drugs Market in China 2014-2019 ($ millions)
- Exhibit 13: Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules
- Exhibit 14: Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules, 2014
- Exhibit 15: Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration
- Exhibit 16: Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration, 2014
- Exhibit 17: Global Colorectal Cancer Drugs Market by Geographical Segmentation 2014
- Exhibit 18: Colorectal Cancer Drugs Market in Americas 2014-2019 ($ millions)
- Exhibit 19: Colorectal Cancer Drugs Market in EMEA 2014-2019 ($ millions)
- Exhibit 20: Colorectal Cancer Drugs Market in APAC 2014-2019 ($ millions)
- Exhibit 21:
- Exhibit 22: Drivers of the Global Colorectal Cancer Drugs Market
- Exhibit 23: Challenges of the Global Colorectal Cancer Drugs Market
- Exhibit 24: Trends of the Global Colorectal Cancer Drugs Market
- Exhibit 25: YoY Growth Rate of the Major Colorectal Cancer Drugs 2010-2014 ($ millions)
- Exhibit 26: F. Hoffmann-La Roche: Product Portfolio
- Exhibit 27: Avastin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
- Exhibit 28: Avastin: Region-wise Revenues 2010-2014 ($ millions)
- Exhibit 29: YoY Revenues and Growth Rate of Avastin in the US 2010-2014 ($ millions)
- Exhibit 30: YoY Revenues and Growth Rate of Avastin in Europe 2010-2014 ($ millions)
- Exhibit 31: YoY Revenues and Growth Rate of Avastin in Japan 2010-2014 ($ millions)
- Exhibit 32: YoY International Revenues and Growth Rate of Avastin 2010-2014 (Except US, Europe, Japan) ($ millions)
- Exhibit 33: Xeloda: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
- Exhibit 34: Xeloda: Region-wise Revenues 2010-2014 ($ millions)
- Exhibit 35: YoY Revenues and Growth Rate of Xeloda in the US ($ millions)
- Exhibit 36: YoY Revenues and Growth Rate of Xeloda in Europe 2010-2014 ($ millions)
- Exhibit 37: YoY Revenues and Growth Rate of Xeloda in Japan 2010-2014 ($ millions)
- Exhibit 38: YoY International Revenues and Growth Rate of Xeloda (Except US, Europe, Japan) ($ millions)
- Exhibit 39: Merck Serono: Product Portfolio
- Exhibit 40: Erbitux: Revenue and YoY Growth Rate except US and Canada 2010-2014 ($ millions)
- Exhibit 41: Erbitux: Region-wise Revenues 2012-2014 ($ millions)
- Exhibit 42: Erbitux: Revenue and YoY Growth Rate in Europe 2012-2014 ($ millions)
- Exhibit 43: Erbitux: Revenue and YoY Growth Rate in Emerging Markets 2012-2014 ($ millions)
- Exhibit 44: Erbitux: Revenue and YoY Growth Rate in ROW 2012-2014 ($ millions)
- Exhibit 45: Bristol-Myers Squibb: Product Portfolio
- Exhibit 46: Erbitux: Revenue and YoY Growth Rate in US and Canada 2010-2014 ($ millions)
- Exhibit 47: Amgen: Product Portfolio
- Exhibit 50: Vectibix: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
- Exhibit 51: Vectibix: Region-wise Revenues 2010-2014 ($ millions)
- Exhibit 52: Sanofi: Product Portfolio
- Exhibit 53: Eloxatin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
- Exhibit 54: Eloxatin: Region-wise Revenues 2010-2014 ($ millions)
- Exhibit 55: YoY Revenues and Growth Rate of Eloxatin in the US ($ millions)
- Exhibit 56: YoY Revenues and Growth Rate of Eloxatin in Europe ($ millions)
- Exhibit 57: YoY Revenues and Growth Rate of Eloxatin in Emerging Markets ($ millions)
- Exhibit 58: YoY Revenues and Growth Rate of Eloxatin in ROW 2010-2014 ($ millions)
- Exhibit 59: Zaltrap: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
- Exhibit 60: Zaltrap: Region-wise Revenue 2013-2014 ($ millions)
- Exhibit 61: Bayer: Product Portfolio
- Exhibit 62: Stivarga: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
- Exhibit 63: Key Takeaways: Global Colorectal Cancer Drugs Market 2015-2019
- Exhibit 64: Amgen: Business Segmentation by Revenue 2013
- Exhibit 65: Amgen: Product Portfolio by Revenue 2013
- Exhibit 66: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
- Exhibit 67: Amgen: Geographical Segmentation by Revenue 2013
- Exhibit 68: Bayer: Business segmentation by revenue 2014
- Exhibit 69: Bayer: Business segmentation by revenue 2013 and 2014 (US$ billion)
- Exhibit 70: Bayer: Geographical segmentation by revenue 2014
- Exhibit 71: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
- Exhibit 72: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
- Exhibit 73: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
- Exhibit 74: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
- Exhibit 75: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
- Exhibit 76: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
- Exhibit 77: Merck Serono: Geographical Segmentation by Revenue 2013
- Exhibit 78: Sanofi SA: Business Segmentation
- Exhibit 79: Sanofi SA: Revenue by Business Segmentation 2013
- Exhibit 80: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
- Exhibit 81: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
